Indication
Hairy Cell
2 clinical trials
3 products
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
MGD024Clinical trial
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
VemurafenibProduct
Obinutuzumab